Saturday, January 19, 2019

Historic Approvals Highlighted at the Second China Innovative Drug Ecosystem Forum 2018

The recent China Innovative Drug Ecosystem Forum, organized by STA Pharmaceutical, a WuXi AppTec company (WuXi STA), was a resounding success with apt timing following the recent announcements of  history-making new...

WuXi AppTec Appoints Edward Hu as Co-CEO

We are pleased to announce the appointment of Mr. Edward Hu as Co-CEO of WuXi AppTec. Mr. Hu will continue to report to Dr. Ge Li, Chairman and CEO of the company. As...

WuXi AppTec Announces Listing of Initial Public Offering of Common Stock on Shanghai Stock...

We are pleased to announce WuXi AppTec's  listing of Initial Public Offering of common stock on the Shanghai Stock Exchange. Proceeds from the IPO will be used to build and expand...

WuXi STA Changzhou Site Passes First U.S. FDA Inspection

We are pleased to announce STA Pharmaceutical Co., Ltd., (WuXi STA), a subsidiary of WuXi AppTec, has secured Pre-Approval Inspection (PAI) for two APIs from the U.S. Food and Drug Administration for its...

WuXi STA Announces to Build a New R&D Center in Shanghai

We are pleased to announce that WuXi's subsidiary, STA Pharmaceutical Co., Ltd, has signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center. The new...

Subscribe to our Newsletter

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS

Cognition Therapeutics: Undaunted Warrior in the Battle Against Alzheimer’s

While the “War on Cancer” has made significant progress, the "War on Alzheimer’s” has proven to be a seemingly implacable foe. The societal costs...